Metastatic melanoma treated with combination anti-cytotoxic T lymphocyte associated protein 4 (CTLA4) and PD-1 therapy leads to increased response rates and progression free survival compared to single agent immunotherapy in particular for PD-L1 negative patients (12, 21–25). The gene discussed is CTLA4; the disease is melanoma.